Brandi Giovanni, de Rosa Francesco, Bolondi Luigi, Agostini Valentina, Di Girolamo Stefania, Nobili Elisabetta, Biasco Guido
Department of Hematology and Oncological Sciences L. e A. Seragnoli, Policlinico Sant'Orsola Malpighi, University of Bologna, Bologna, Italy.
Tumori. 2010 Nov-Dec;96(6):1028-30.
Hepatocellular carcinoma (HCC) is a highly vascular tumor which is poorly responsive to standard systemic chemotherapy. Recently, various antiangiogenic targeted agents have shown promising activity at different levels of evidence in patients with advanced HCC, suggesting that such treatments might be effective.
Since chemotherapy administered with metronomic schedules inhibits angiogenesis, we treated a 64-year-old man with advanced HCC with metronomic capecitabine. After only two months of treatment the HCC nodules disappeared on ultrasonography. This finding was confirmed by a computed tomography scan. After more than three years the patient is still in treatment with minimal toxicity and maintains a complete remission.
Our case report suggests that metronomic capecitabine may be effective in advanced HCC patients while being also well tolerated. This is important, given the frequent comorbidities of HCC patients.
肝细胞癌（HCC）是一种血管丰富的肿瘤，对标准全身化疗反应不佳。最近，各种抗血管生成靶向药物在晚期HCC患者中，在不同证据水平上均显示出有前景的活性，提示此类治疗可能有效。
由于采用节拍化疗方案给药的化疗可抑制血管生成，我们用节拍性卡培他滨治疗了一名64岁的晚期HCC男性患者。仅治疗两个月后，超声检查显示HCC结节消失。计算机断层扫描证实了这一发现。三年多来，该患者仍在接受治疗，毒性极小，维持完全缓解状态。
我们的病例报告提示，节拍性卡培他滨可能对晚期HCC患者有效，且耐受性良好。鉴于HCC患者常伴有合并症，这一点很重要。
Zotero 插件